HistoIndex AI Analysis Confirms Fibrosis Improvement in D&D Pharmatech Phase 2 MASH Trial

June 18, 2026
HistoIndex's AI-based quantitative analysis confirmed significant liver fibrosis improvement in D&D Pharmatech's Phase 2 trial of zabopegdutide for MASH, reinforcing earlier histopathological findings.

HistoIndex and D&D Pharmatech announced positive results from an AI-based quantitative analysis of liver biopsy samples from the Phase 2 clinical trial of zabopegdutide, according to a press release. The investigational treatment targets metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease.

HistoIndex used its proprietary qFibrosis tool to evaluate fibrosis changes in 48-week liver biopsies from 27 patients. The analysis showed that 81.8% of patients treated with zabopegdutide achieved at least a one-stage improvement in fibrosis compared to 18.8% in the placebo group. The relative change in qFibrosis continuous score was a 41% reduction for treated patients versus a 9.5% increase for the placebo group.

These AI-based findings align with previous pathologist assessments that demonstrated improvements in fibrosis and MASH resolution after 48 weeks of treatment. The results support the potential of zabopegdutide as an effective therapy for metabolic liver disease and highlight the role of AI in improving precision and reproducibility in clinical fibrosis assessment.

Additional details from HistoIndex’s data will be presented at upcoming scientific conferences.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

06/18
Vali Health Raises $6 Million to Build AI Infrastructure for Home Care
06/18
Lunai Bioworks CEO Updates Shareholders on Defense Contracts, AI Biodefense, and Legal Action
06/18
LG AI Research and D&D Pharmatech Partner on AI-Driven Oral Peptide Drugs
06/18
Icarus Medical Raises $7.2 Million Series A to Expand Orthopedic Bracing Technology
06/18
Coreline Soft and Mint Medical Partner on AI Lung Cancer Screening Integration

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like